INSIGHTS ON CLINICAL TRIAL PARTNERING

• Ergomed's Solutions To The Challenges of Oncology Trials

  Explore a pivotal Phase III global clinical trial investigating neoadjuvant immunotherapy for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

• Accelerating Clinical Trials Through Streamlined Confidential Disclosure Agreements

  In this presentation, Dr. Christine Senn addresses the persistent challenge of study startup delays by focusing on a primary legal hurdle: the Confidential Disclosure Agreement (CDA).

• Specialized Site Network For Early-Phase Oncology Success

  Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Yet, too often, the operational burden falls on clinical sites―already overworked and stretched thin. Within large, volume-driven CRO networks, this creates a system that prioritizes scale over quality, offering minimal site support, delaying timelines, and ultimately compromising trial outcomes.

• 10 Roadblocks To Traditional Vendor Selection And How ClinAI Solves Them

  Vendor selection in clinical trials is a pivotal process. Explore ten widespread inefficiencies in the current approach and how you can resolve them.

• From Friction To Partnership: What It Really Takes To Become The Sponsor of Choice

  7/17/2026

  Sponsors depend on sites to recruit patients, execute protocols, and collect high-quality data. In this candid panel discussion, we explore what makes sites want to work with a sponsor.

• Switching IRT/RTSM Providers Shouldn't Feel Like Moving Mountains | Korio Makes It Easy

  3/25/2026

  Unveil how structured, repeatable processes can turn RTSM migrations from high‑risk undertakings into predictable transitions.

• Faster Starts, Stronger Finish: Operational Excellence In NSCLC

  5/22/2026

  In NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.

• Breaking Silos In Drug Development: The Power Of An Integrated Model

  5/11/2026

  Experts share how Altasciences' integrated Preclinical/Clinical model results in fewer handoffs, greater continuity, and accelerated progress from the nonclinical phase to first-in-human trials.

• Vendor Selection Bias: Why Structured Decisions Often Fail

  12/22/2025

  Learn how subtle influences derail decisions and discover proven safeguards that promote transparency, accountability, and shared ownership for better trial outcomes.